TITLE

Methylnaltrexone and opioid-induced constipation

AUTHOR(S)
Lohr, Lisa
PUB. DATE
October 2008
SOURCE
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p6
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article presents a discussion on the use of methylnaltrexone to treat opioid-induced constipation (OIC). This condition is caused by interactions among various drugs including anticonvulsants and phenothiazines. The U.S. Food & Drug Administration (FDA) approved the use of methylnaltrexone to cure OIC.
ACCESSION #
34781559

 

Related Articles

  • Methadone Alert.  // JAMA: Journal of the American Medical Association;1/24/2007, Vol. 297 Issue 4, p354 

    The article states that the U.S. Food and Drug Administration has issued an alert about reported adverse events of patients receiving the drug methadone for the treatment of chronic pain. Patients suffered respiratory depression, cardiac arrhythmias, and death from taking methadone. The...

  • FDA Announces Class-Wide Label Changes to Extended-Release and Long-Acting Opioids. McKnight, Whitney // Neurology Reviews;Oct2013, Vol. 21 Issue 10, p26 

    The article informs that the U.S. Federal and Drug Administration (FDA), responsible for protecting and promoting public health had announced class-wide label changes to extended-release and long-acting opioid analgesics for the treatment of chronic pain. It further reports that changes to...

  • New treatment for cancer patients and constipation.  // Drug Formulary Review;Dec2008, Vol. 24 Issue 12, p104 

    The article reports on the peripheral-acting mu opioid receptor antagonists, a new class of drugs for cancer patients and other advanced illness patients. The first drug to be approved in this class is the methylnaltrexone, which aids advanced ill patients who suffer from opioid-induced...

  • Progenics gets sNDA for Opioid-Induced Constipation.  // Biotech Business;Aug2011, Vol. 24 Issue 8, p6 

    The article focuses on Progenics Pharmaceuticals' supplemental New Drug Application submission to the U.S. Food and Drug Administration for the approval of RELISTOR, which is a drug that is meant to treat the underlying cause of opioid-induced constipation (OIC). The drug is already used in the...

  • FDA approves drug to treat opioid-induced constipation.  // Hem/Onc Today;5/25/2008, Vol. 9 Issue 9, p59 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of methylnaltrexone bromide subcutaneous injection for the treatment of opioid-induced constipation in patients receiving palliative care. According to Joyce Korvick of the FDA, the new drug will be helpdul to...

  • A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly. Gras-Miralles, Beatriz; Cremonini, Filippo // Clinical Interventions in Aging;2013, Vol. 8, p191 

    Chronic constipation is a common disorder in the general population, with higher prevalence in the elderly, and is associated with worse quality of life and with greater health care utilization. Lubiprostone is an intestinal type-2 chloride channel activator that increases intestinal fluid...

  • FDA Releases Guidance on Opioids. Haigney, Susan // BioPharm International;Feb2013, Vol. 26 Issue 2, p8 

    The article offers information on the U.S. Food and Drug Administration (FDA) regarding the release of an official document titled "Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling, Draft Guidance" as its effort to help industry develop abuse-deterrent opioids.

  • FDA approves extended-release oxycodone combo to deter abuse. Chamberlin, Kevin W. // Drug Topics;Dec2014, Vol. 158 Issue 12, p64 

    The article reports that the U.S. Food & Drug Administration (FDA) approved an opioid analgesic with an abuse deterrent on July 23, 2014, for treatment of severe pain.

  • Introduction: Opioid-Induced Constipation. Lembo, Anthony J // American Journal of Gastroenterology;Aug2014 Supplement, Vol. 109, p2 

    The article focuses on opioid-induced constipation (OIC) and mentions that it is the most common side effect of opioid that affects approximately 40% of patients with non-cancer pain who use this treatment. Topics discussed include symptoms of the OIC, U.S. Food and Drug Administration's...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics